<p>Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer</p>

Abstract

Our study identified that the gene of <i>MSX1</i> promised to be the specific indicator and therapeutic target for progestin resistance. This would shed new light on the underlying biological mechanism to overcome progestin resistance of endometrial cancer.